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PURPOSE. The purpose of this study was to assess whether non-chlamydial bacterial infection is
associated with progression of trachomatous scarring in adults.
METHODS. This was a cohort study involving 800 participants in northern Tanzania who
underwent clinical examination, photography, and conjunctival swab collection for
microbiology over a 24-month period. Samples for microbiology were inoculated onto blood
and chocolate agar, and Chlamydia trachomatis was detected by PCR. Progression was
determined by comparison of baseline to 24-month photographs.
RESULTS. C. trachomatis was detected in only four participants at baseline. At 24 months, 617
participants (77.1%) were followed up. Of those seen at 24 months, 452 could be reliably
assessed. Definite scarring progression (progressors) was seen in 345 (55.9%); there was no
progression (nonprogressors) in 107 (17.3%). Using combined baseline and 12-month
microbiology results, progressors had significantly higher levels of commensal and pathogenic
bacterial organisms detected compared with nonprogressors. After adjusting for age, baseline
scarring, and ethnicity, there was weak evidence (P ¼ 0.07) that the bacteria category was
associated with scarring progression (commensal organisms only: odds ratio [OR] ¼ 1.61;
95% confidence interval [CI]: 0.90 to 2.89; pathogenic organisms either with or without
commensal: OR ¼ 2.39; 95% CI: 1.10 to 5.16).
CONCLUSION. The findings were consistent with the possibility that trachomatous scarring in
adults is associated with the presence of non-chlamydial bacterial organisms, particularly
pathogenic organisms. C. trachomatis was detected very infrequently and may not be an
important factor in the pathogenesis of scarring progression in adults. This has implications
for trachoma control programs, which largely concentrate on reducing C. trachomatis levels
and transmission.
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Trachoma is caused by recurrent episodes of infection withChlamydia trachomatis. In childhood, infection is charac-
terized by a follicular-papillary conjunctivitis.1 Such individuals
are at risk of developing the scarring complications of trachoma
in later life, including conjunctival scarring, entropion (the
eyelid turning in toward the globe), and trichiasis (eyelashes
rubbing against the globe). The result is corneal scarring and
loss of vision. The development of scarring is a cumulative
process. Therefore, the prevalence and severity of scarring
increases with age. Trachoma control efforts are primarily
focused on reducing C. trachomatis prevalence and transmis-
sion with the use of mass antibiotic administration and the
improvement of hygiene and sanitation.
Infection with C. trachomatis shows a consistent relation-
ship with active trachoma in children, especially in treatment-
na¨ıve populations.2 In contrast, the pathogenesis of progressive
scarring in adults is less clear. C. trachomatis is only
infrequently detected in ocular surface samples from adults
who have trachomatous scarring, with detection rates some-
times being close to zero.3–7 A recent review on trachoma
progression found only one study providing evidence that
children with baseline C. trachomatis infection were at an
increased risk of subsequent scarring and no studies demon-
strating that progression of established scarring was associated
with C. trachomatis.7,8 Despite this, adults with established
scarring show progression of that scarring with the develop-
ment of sight-threatening complications. Incident trichiasis has
been observed in The Gambia after C. trachomatis had been
effectively eliminated.9 Recent cohort studies from Ethiopia and
Tanzania in adults found scarring progression in around one
quarter of subjects after 2 years, despite negligible C.
trachomatis DNA detection.6 This raises the question about
whether there might be other factors that can contribute to
progressive scarring processes.
A strong association has been found in longitudinal studies
between conjunctival inflammation and progressive scarring,
indicating a central role in the pathogenesis of cicatricial
trachoma. The Ethiopian and Tanzanian scarring trachoma
cohort studies reported an odds ratio (OR) of 5.8 (P < 0.0001)
for progressive scarring with increasing episodes of clinical
inflammation. Although the pathogenesis of scarring trachoma
in adults is relatively poorly understood, recent studies have
suggested that innate immune mechanisms driven by epithelial
responses may be important.1,10–12 Non-chlamydial bacterial
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infection of the conjunctiva has been found to be associated
with the presence of clinically visible inflammation, with
trachomatous scarring (without trichiasis), with trachomatous
trichiasis, and with recurrence after trichiasis surgery.3,9,13–16
This non-chlamydial bacterial infection is associated with the
elevated expression of a variety of proinflammatory mediators
and modifiers of the extracellular matrix.10 Inoculation of
bacteria into eyes with scarring in a monkey model of
trachoma caused a more marked and prolonged inflammatory
reaction compared with control animals.17 In this study, we
examined whether non-chlamydial bacteria cultured from the
conjunctiva were associated with progression of trachomatous
scarring over time.
METHODS
Ethical Approval
This study adhered to the tenets of the Declaration of Helsinki.
It was approved by the Ethics Committees of the Tanzanian
National Institute for Medical Research, the Kilimanjaro
Christian Medical Centre, and the London School of Hygiene
& Tropical Medicine. The study was explained to potential
study subjects, and written information in Kiswahili was
provided. Informed consent was obtained before enrollment.
If the participant was unable to write, consent was recorded by
witnessed thumbprint, as approved by the Ethics Committees.
Participant Recruitment and Examination
Recruitment of participants and clinical examination proce-
dures have been previously described.6 Briefly, 800 adults with
trachomatous upper tarsal conjunctival scarring, but without
trichiasis, from a trachoma endemic region in Siha District,
Northern Tanzania, were recruited into a 2-year longitudinal
cohort study. Study participants were assessed at baseline and
6, 12, 18, and 24 months, including clinical examination and
high-resolution digital photography of the everted upper tarsal
conjunctiva of the left eye (Nikon D200 camera with Nikon
105-mm macro lens and Nikon R1 flash system; Nikon, Tokyo,
Japan). Grading was performed using the detailed ‘‘FPC’’ World
Health Organization Trachoma Grading System, with a more
detailed scarring grading system as previously described.13,18,19
The left conjunctiva was anesthetized with preservative-free
proxymetacaine 0.5% eye drops (Minims; Chauvin Pharmaceu-
ticals, London, UK). A Rayon-tipped swab sample was
collected for microbiological analysis from the inferior
conjunctival fornix, immediately placed into Amies-Charcaol
transport media (Sterilin, Caerphilly, UK), and kept at ambient
temperature. An upper tarsal conjunctival swab was also
collected (Dacron polyester-tipped; Hardwood Products Com-
pany, Guildford, ME, USA) and put into a dry tube for C.
trachomatis detection. These samples were kept on ice packs
until frozen later the same day at 808C.
Scarring Progression
To determine whether progression in conjunctival scarring had
occurred, the baseline and 24-month tarsal conjunctival
photographs were directly compared side by side by two
ophthalmologists working independently. Individuals with
progressive scarring, progressors, were defined as those with
clear photographic evidence of increased conjunctival scarring
at 24 months. Nonprogressors clearly did not have photo-
graphic evidence of scarring progression. Any disparities in
progression status were discussed and agreement reached.
Grading was performed with masking to all laboratory results.
Microbiology Samples and Analysis
C. trachomatis DNA was detected using a PCR-based assay
(Amplicor CT/NG Test; Roche Diagnostics, Indianapolis, IN,
USA) with previously described modifications.20 Samples for
culture were inoculated onto blood and chocolate agar later on
the day of collection (rarely more than 6 hours) and incubated
at 378C for 48 hours. Culture isolates were identified by
standard microbiological techniques. In keeping with previous
work, coagulase-negative staphylococci, Corynebacterium
spp., Streptococcus viridans, and Bacillus spp. were designat-
ed as commensal organisms.13 Other organisms were catego-
rized as pathogenic at this site.
Sample Size and Data Analysis
This study was part of a larger series of related studies on the
pathogenesis of trachomatous scarring with the sample size
calculated to encompass these other components. Data were
entered into Access 2007 (Microsoft, Redmond, WA, USA) and
analysed using STATA 14.0 (StataCorp LP, College Station, TX,
USA). Fisher’s exact test was used to determine strength of
association for demographic and baseline characteristics with
scarring progression. Culture results at baseline and 12 months
were combined to form a single parameter with three
categories. Individuals with a pathogenic organism at either
time point were classified as the pathogenic group; individuals
with a commensal but without a pathogenic organism at either
time point were classified as the commensal group. If data
were missing at one of the time points, the individual was
classified using the data from the available single time point. If
data were missing at both time points, the observation was
classified as missing. Logistic regression models were used to
estimate univariable ORs and 95% confidence intervals (CIs)
for factors associated with scarring progression from baseline
to 24 months. A multivariable logistic regression model was
generated including factors independently associated with
scarring progression, using a threshold of P < 0.1 as the
criteria for inclusion. Likelihood ratio tests were used to assess
the strength of association of each factor with the outcome and
tests for nonlinearity were conducted to assess whether fitting
age category and scarring as continuous variables provided
adequate fits to the data.
RESULTS
Initially, 800 individuals with conjunctival scarring were
recruited. Only four of these individuals were positive for C.
trachomatis by PCR at baseline. At the 24-month follow-up,
617 (77.1%) of the study participants were seen and had
photographs taken (the remainder had either died [18], moved
away [72], or were absent/refused examination at follow-up
[93]), with a mean follow-up time of 681 days (SD, 39 days).
There were 452 of 617 (73.3%) individuals who had high-
quality photographs at both baseline and 24 months, in whom
the masked graders were confident that there was either
progression in scarring, or no scarring progression, by 24
months. Baseline demographic details of those included and
excluded from subsequent analyses are shown in Table 1; there
was no significant differences between the two groups. There
were 345 progressors and 107 nonprogressors. Progressors
tended to be older than nonprogressors, had less education,
and had more severe grades of conjunctival scarring at baseline
(Table 2).
Microbiological culture results at baseline and 12 months,
stratified by scarring progression status, are shown in Table 3.
Progressors had a higher prevalence of both commensal and
pathogenic organisms at both baseline and 12 months. The
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remaining results presented use the combined baseline/12-
month results. Table 4 shows univariable ORs and a
multivariable logistic regression model for factors associated
with scarring progression by 24 months. After adjusting for
age, baseline scarring, and ethnicity, there was some evidence
that the bacteria category was associated with scarring
progression (commensal organisms only: OR ¼ 1.61; 95% CI:
0.90 to 2.89; pathogenic organisms either with or without
commensal: OR ¼ 2.39; 95% CI: 1.10 to 5.16).
Table 5 shows progression by combination of pathogenic
and commensal organisms. Participants with pathogenic
organisms alone were most likely to be progressors (OR ¼
3.82; 95% CI: 0.98 to 14.84 compared with nonprogressors),
although there were only 12 participants in this category.
DISCUSSION
There is clear evidence linking conjunctival infection with C.
trachomatis to active trachoma in children.2,21 In contrast, the
relationship between C. trachomatis infection and the
pathogenesis of progressive trachomatous scarring in older
people is less clearly defined.1,7 In keeping with previous
work, in the current study, we only very infrequently detected
C. trachomatis in adults with scarring. Previous work has
shown that non-chlamydial bacterial infection is found more
frequently in those with trichiasis and is associated with
recurrence of trichiasis after surgery.3,14–16 We previously
found that individuals with trachomatous conjunctival scarring
(without trichiasis) more frequently have conjunctival com-
mensal and pathogenic organisms detected compared with
controls.13 A recent study found no association between
conjunctival scarring and non-chlamydial bacterial carriage.22
However, this study was undermined by only 14% of all swabs
detecting a bacterial isolate, a much lower detection rate
compared with other conjunctival bacteriology studies and by
failing to find any association between bacterial carriage and
the presence of trichiasis, also in marked contrast to other
studies.3,14–16,23–26
The study reported in the current paper found some
evidence that the presence of non-chlamydial bacteria on the
conjunctival surface at baseline/12 months was associated with
scarring progression and that the estimated effect of patho-
genic organisms was greater than that of commensal organ-
isms. Post hoc analysis found no evidence of a difference
between individuals with pathogenic organisms and those with
commensal organisms only, and if progression of scarring was
modeled using culture of any organism (either commensal or
pathogenic), compared with no culture, then an OR for
progression (after adjusting for the age group, ethnicity, and
baseline scarring) was found of 1.75 (95% CI: 0.99 to 3.06; P¼
0.05). Differentiating between commensal and pathogenic
TABLE 1. Demographic Characteristics of the Cohort Study Partici-
pants, Subdivided Into Those Included and Excluded From Progression
Analysis
Parameter
Included in
the Analysis
Excluded From
the Analysis
P
Value†n (%)* n (%)*
Sex N ¼ 452 N ¼ 348 0.30
Female 287 (63.5) 208 (59.8)
Male 165 (36.5) 140 (40.2)
Age group N ¼ 452 N ¼ 348 0.38
18–25 51 (11.3) 53 (15.2)
25–35 99 (21.9) 64 (18.4)
35–45 104 (23.0) 70 (20.1)
45–55 70 (15.5) 59 (17.0)
55–65 56 (12.4) 39 (11.2)
>65 72 (15.9) 63 (18.1)
Ethnicity N ¼ 452 N ¼ 348 0.38
Maasai 330 (73.7) 270 (77.6)
Chagga 61 (13.6) 40 (11.5)
Meru 22 (4.9) 10 (2.9)
Other 35 (7.8) 28 (8.1)
Any formal
education
N ¼ 452 N ¼ 348 0.88
157 (34.8) 119 (34.2)
Culture result at
baseline
N ¼ 447 N ¼ 345 0.93
No organism 210 (47.0) 159 (46.1)
Commensal
organism only
208 (46.5) 165 (47.8)
Pathogenic 6
commensal
organism
29 (6.5) 21 (6.1)
Culture result at 12
months
N ¼ 365 N ¼ 204 0.84
No organism 185 (50.7) 109 (53.4)
Commensal
organism only
147 (49.3) 78 (38.2)
Pathogenic 6
commensal
organism
33 (9.0) 17 (8.3)
* Note column percentages.
† Using Fisher’s exact test.
TABLE 2. Demographic Characteristics and Baseline Scarring Grade,
Subdivided Into Nonprogressors and Progressors
Parameter
Nonprogessors Progressors
P Value†
(N ¼ 345) (N ¼ 107)
n (%)* n (%)*
Sex 0.36
Female 215 (62.3) 72 (67.3)
Male 130 (37.7) 35 (32.7)
Age group (y) 0.001
18–25 43 (12.5) 8 (7.5)
25–35 84 (24.5) 15 (14.0)
35–45 86 (24.9) 18 (16.8)
45–55 51 (14.8) 19 (17.8)
55–65 38 (11.0) 18 (16.8)
>65 43 (12.5) 29 (27.1)
Mean age in years,
(95% CI)
43.3 (41.5–45.1) 51.0 (47.6–54.4) <0.001
Ethnicity 0.06
Maasai 251 (73.6) 79 (73.8)
Chagga 52 (15.3) 9 (8.4)
Meru 17 (5.0) 5 (4.7)
Other 21 (6.2) 14 (13.1)
Formal education 0.02
None 214 (62.2) 80 (74.8)
Any 130 (37.8) 27 (25.2)
Scarring grade at baseline <0.001
1 100 (29.0) 10 (9.4)
2 149 (43.2) 32 (29.9)
3 71 (20.6) 41 (38.3)
4 12 (3.5) 15 (14.0)
5 13 (3.8) 9 (8.4)
* Note column percentages.
† Using Fisher’s exact test.
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organisms can be challenging, however. Previous work found
that organisms classified as pathogenic were strongly associat-
ed with a marked clinical inflammatory response, whereas
those classified as commensal were not.13 However, organisms
normally considered to be commensal at a particular site may,
under some conditions, act in pathogenic manner.27 It has
been postulated that when such bacteria reach a threshold
population level, pathogenic mechanisms are triggered.28 It is
plausible that ‘‘commensal’’ organisms act in a symbiotic
manner in the normal, healthy ocular surface, but in eyes with
trachomatous conjunctival scarring, they interact with the
ocular surface in different ways, leading to proinflammatory
effects. For example, previously we found that in eyes with
conjunctival scarring, there are marked changes in the
expression of several mucins.11 This may lead to altered
barrier protection by the mucin layer, resulting in more direct
interaction between ocular surface bacteria and the epitheli-
um, potentially promoting inflammation.
Bacterial infection of the ocular surface triggers innate
immune responses.29,30 Previous work has suggested a role for
innate immune mechanisms in driving the scarring process in
trachoma. Human conjunctival transcriptome studies in both
active and scarring trachoma have shown prominent innate
immune responses.11,12 Animal studies have shown neutrophil
infiltration of the genital tract tissue following C. trachomatis
inoculation and that the intensity of the infiltrate was related to
subsequent fibrotic sequelae.31,32 Toll-like receptor-2 knockout
mice were able to clear infection but had markedly reduced
late oviduct pathology.33 A guinea pig model of trachoma
looking at neutrophil depletion showed less inflammation
clinically and fewer mucosal erosions histologically.34
Active trachoma is characterized by histologic and molec-
ular inflammatory changes in the conjunctiva, which may be
maintained over prolonged periods by repeated infection with
C. trachomatis.10,35 It is possible that with the development of
conjunctival scarring, abnormal innate proinflammatory re-
sponses also develop.6 The anatomical and morphologic
changes to the conjunctival surface may render it more
susceptible to interaction with bacteria, leading to more
inflammation. Conjunctival fibroblasts from patients with
scarring trachoma display profibrotic and proinflammatory
features, in particular, an increased interleukin-6 expression
and secretion.35 It is possible that these pathways are
stimulated by non-chlamydial bacteria, leading to chronic
inflammation and progressive fibrosis.
This study has several limitations. There was some loss to
follow-up; however, this is to be expected in a study of this
kind, and there were no systematic differences between those
followed up and those lost to follow-up. Detection of
organisms was limited to those known and looked for, and
we did not include a specific culture media for fungi,
potentially underestimating their role. The use of molecular
detection techniques may potentially have led to different
results. The severity of scarring in the study participants was
relatively mild, reflecting the mesoendemic level of trachoma
in this population. It would be interesting to compare results in
a hyperendemic area with more severe conjunctival scarring,
as this may reveal a stronger relationship with non-chlamydial
bacterial infection. Pathogenic organisms were detected
relatively infrequently, and we believe that a larger sample
size may well have found a stronger association between
scarring progression and infection.
TABLE 3. Culture Results at Baseline, 12 Months, and Combined
Baseline/12 Months, According to Scarring Progression
Parameter
Nonprogessors Progressors
P Value†n (%*) n (%*)
Baseline N ¼ 341 N ¼ 106 0.04
No organism 171 (81.4) 39 (18.6)
Commensal
organism only
151 (72.6) 57 (27.4)
Pathogenic 6
commensal organism
19 (65.5) 10 (34.5)
12 months (N ¼ 365) N ¼ 277* N ¼ 88* 0.36
No organism 144 (77.8) 41 (22.2)
Commensal organism
only
111 (75.5) 36 (24.5)
Pathogenic 6
commensal organism
22 (66.7) 11 (33.3)
Combined baseline and
12 months
N ¼ 345* N ¼ 107* 0.02
No organism 116 (84.1) 22 (15.9)
Commensal organism
only
189 (73.8) 67 (26.2)
Pathogenic 6
commensal organism
40 (69.0) 18 (31.0)
* Note row percentages.
† Using Fisher’s exact test.
TABLE 4. Univariable ORs and Multivariable Logistic Regression Model for Scarring Progression
Risk Factor
Univariable Analysis Multivariable Analysis
OR 95% CI P* OR 95% CI P*
Any formal education 0.56 0.34–0.90 0.018 †
Age group 1.36 1.19–1.57 <0.001 1.27 1.09–1.49 0.003
Ethnicity 0.056 0.010
Maasai 1.00 – 1.00 – –
Chaga 0.55 0.26–1.17 0.35 0.16–0.80
Meru 0.93 0.33–2.61 0.68 0.21–2.14
Other 2.12 1.03–4.36 1.81 0.82–4.00
Baseline scarring 1.90 1.54–2.35 <0.001 1.81 1.44–2.27 <0.001
Type of bacterial organism cultured‡ 0.016 0.073
None 1.00 – 1.00 – –
Commensal only 1.96 1.14–3.37 1.61 0.90–2.89
Pathogenic 6 commensal organism 2.49 1.20–5.13 2.39 1.10–5.16
* Using likelihood ratio tests.
† Lost statistical significance in the adjusted multivariable model.
‡ Using the combined baseline/12-month results.
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In conclusion, these cohort study data are consistent with
the possibility that non-chlamydial bacterial infection is
associated with progression of trachomatous conjunctival
scarring. We hypothesise that this is through impaired ocular
surface defences and increased vulnerability to pro-inflamma-
tory stimulation, although future studies would be needed to
formally test this hypothesis.
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